Intermountain Health Expands Access to Experimental Pancreatic Cancer Drug
Event summary
- 10 Intermountain Health hospitals in Colorado, Montana, and Utah are joining a national Expanded Access Protocol to provide eligible patients with advanced pancreatic cancer access to daraxonrasib.
- Daraxonrasib nearly doubled survival rates from 6.7 months to 13.2 months in initial clinical trials for metastatic pancreatic cancer.
- The drug targets KRAS mutations present in over 90% of pancreatic cancers, shutting down growth signals that drive tumor proliferation.
- Intermountain Health was selected based on expertise in precision medicine and comprehensive cancer treatment.
The big picture
Intermountain Health's expansion of access to daraxonrasib underscores a broader industry trend toward targeted therapies in oncology. The move highlights the growing emphasis on precision medicine, where treatments are tailored to specific genetic mutations. This initiative also reflects the increasing collaboration between healthcare providers and regulatory bodies to expedite access to promising therapies for deadly cancers.
What we're watching
- Clinical Efficacy
- How daraxonrasib's survival rate improvements will translate into broader commercial success and regulatory approval.
- Market Adoption
- The pace at which other healthcare systems adopt the Expanded Access Protocol for daraxonrasib.
- Precision Oncology Shift
- Whether this initiative accelerates the shift toward precision oncology in treating pancreatic cancer.
Related topics